Approved Risk Evaluation and Mitigation Strategies (REMS)

REMS@FDA

Contact Us | REMS Resources | Get REMS Email Alerts | Reports & Data Files

Buprenorphine Transmucosal Products for Opioid Dependence (BTOD)

Shared System REMS

REMS last update: 10/31/2018

Products
Goals
Summary
REMS Materials
Update history

What medicines are included in the REMS?

Product Name	Application Number	Application Holder	Added to REMS	DailyMed Link	FDA Link
Bunavail (buprenorphine and naloxone) ( PI and MG at DailyMed , Info at Drugs@FDA )	NDA 205637	BDSI	06/06/2014	12b963dd-f189-11e3-ac10-0800200c9a66	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205637
Zubsolv (buprenorphine and naloxone) ( PI and MG at DailyMed , Info at Drugs@FDA )	NDA 204242	OREXO US INC	09/04/2013	5f5cfcfe-d52b-49e6-8fe4-550477332dd2	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204242
buprenorphine ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 201760	SUN PHARM INDS LTD	01/29/2016	9fd1f18f-0b0f-4059-b603-19ecbf0ed63a	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201760
buprenorphine ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 207276	RHODES PHARMS	03/27/2017	da90618a-5621-4b15-bc48-9dcc631418de	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207276
buprenorphine and naloxone ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 201633	SUN PHARM INDS LTD	08/05/2016	91b68606-05de-4586-ae31-07e8cc9160cf	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201633
buprenorphine and naloxone (Info at Drugs@FDA)	ANDA 207000	SPECGX LLC	12/13/2017
buprenorphine and naloxone (Info at Drugs@FDA)	ANDA 205806	DR REDDYS LABS SA	06/14/2018
buprenorphine and naloxone (Info at Drugs@FDA)	ANDA 207607	MYLAN TECHNOLOGIES	06/14/2018
buprenorphine and naloxone (Info at Drugs@FDA)	NDA 208042	TEVA PHARMS USA	09/07/2018
buprenorphine and naloxone ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 205022	LANNETT CO INC	09/19/2016	14eaa94a-cc8a-4e1e-8cfb-5c976c96c606	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205022
buprenorphine hydrochloride ( Info at Drugs@FDA )	ANDA 090279	CASI PHARMS INC	06/10/2015		http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=090279
buprenorphine hydrochloride ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 090622	ETHYPHARM	02/22/2013	a891f3ff-5cad-4e92-b4c4-d5108c8df550	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=090622
buprenorphine hydrochloride ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 090819	ACTAVIS ELIZABETH	02/19/2015	03819118-86f6-4329-adaf-4599e7b71f46	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=090819
buprenorphine hydrochloride ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 201066	MYLAN PHARMS INC	03/06/2015	7a85f424-9d83-49d9-8a17-478abce6fddd	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=201066
buprenorphine hydrochloride ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 078633	WEST-WARD PHARMS INT	02/22/2013	1bf8b35a-b769-465c-a2f8-099868dfcd2f	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=078633
buprenorphine hydrochloride ( Info at Drugs@FDA )	ANDA 090360	BARR	02/22/2013		http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=090360
buprenorphine hydrochloride and naloxone hydrochloride dihydrate ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 203136	AMNEAL PHARMS	02/22/2013	17b63f10-c9df-44be-80fa-6f1c305583b8	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203136
buprenorphine hydrochloride and naloxone hydrochloride dihydrate ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 091149	TEVA PHARMS USA	09/09/2014	b39c724f-7dc1-4213-8671-83c34a82268a	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=091149
buprenorphine hydrochloride and naloxone hydrochloride dihydrate ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 204431	ETHYPHARM USA CORP	10/16/2015	47236a95-ba0b-4f6a-b406-858cabc726df	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204431
buprenorphine hydrochloride and naloxone hydrochloride dihydrate ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 203326	WEST-WARD PHARMS INT	06/27/2014	713db2c6-0544-4633-b874-cfbeaf93db89	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203326
buprenorphine hydrochloride and naloxone hydrochloride dihydrate ( PI and MG at DailyMed , Info at Drugs@FDA )	ANDA 091422	ACTAVIS ELIZABETH	02/22/2013	6cccf229-9611-4b6f-8f1b-acc8ff1ed3f8	http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=091422
buprenorpine and naloxone (Info at Drugs@FDA)	ANDA 205299	DR REDDYS LABS SA	06/14/2018

What is the purpose of the REMS?

The goals of the Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) REMS are to:

Mitigate the risks of accidental overdose, misuse, and abuse.
Inform prescribers, pharmacists, and patients of the serious risks associated with buprenorphine-containing products.

What do participants need to know?

Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.

View application holder(s) REMS Website

Health Care Providers who prescribe or dispense buprenorphine transmucosal products for opioid dependence (BTOD) must

Before treatment initiation (first dose)	Assess the patient’s condition to verify the patient meets the diagnostic criteria for opioid dependence. Counsel the patient on the risks described in the professional information and Medication Guide and safe storage of the medication. Complete the Appropriate Use Checklist. Retain a completed copy in the patient’s record or by using another method (e.g. electronic health record) specific to the prescriber’s office practice.
During treatment; at the first visit following induction	Prescribe a limited amount of medication.
During treatment; at a return visit scheduled at intervals commensurate with patient stability	Assess the patient’s compliance with the prescribed medication, appropriateness of the dosage prescribed, whether patient is receiving the necessary psychosocial support, and whether patient is making adequate progress towards treatment goals Complete the Appropriate Use Checklist. Retain a completed copy in the patient’s record or by using another method (e.g. electronic health record) specific to the prescriber’s office practice.

Patients who are prescribed buprenorphine transmucosal for opioid dependence (BTOD) products

Before the first prescription	Receive counseling from the prescriber on the risks and safe storage of the medication.
During treatment; at a time interval determined by your prescriber	Be monitored for compliance with the prescribed medication, appropriateness of the dosage prescribed, assessment of whether receiving the necessary psychosocial support, and whether making adequate progress towards treatment goals

What materials are included in the REMS?

The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers. For a specific Medication Guide of a product in the Buprenorphine Transmucosal Products for Opioid Dependence (BTOD) REMS, see the DailyMed link on the Products tab.

Material Name	Material Name Link
Appropriate Use Checklist (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_Appropriate_Use_Checklist.pdf
Dear Pharmacist Letter (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_Dear_Pharmacist_Letter.pdf
Dear Prescriber Letter (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_Dear_Prescriber_Letter.pdf
Pharmacist Brochure (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_Pharmacist_Brochure.pdf
Prescriber Brochure (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_Prescriber_Brochure.pdf
REMS Document (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_REMS_Document.pdf
REMS Full (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_REMS_Full.pdf
REMS Website Screenshots (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/rems/BTOD_2018_10_31_REMS_Website_Screenshots.pdf

What updates have been made to the REMS?

Date	Summary of change
10/31/2018	Modified to align the REMS document and materials with the approved labeling. Those labeling changes pertained to the risks of life-threatening respiratory depression and death with concomitant use of buprenorphine with benzodiazepines or other CNS depressants, and additional revisions to the Package Insert.
09/07/2018	Modified to add Cassipa (buprenorphine and naloxone) product information.
05/23/2017	Modified to align the REMS document and materials to the labeling approved on December 16, 2016, as well as additional minor modifications.
01/23/2017	Revised to correct a typographical error(s).
10/04/2016	Modified to include the proposed new strength into the Dose Comparison Chart included in both the Prescriber Brochure, "Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers" and the Pharmacist Brochure, "Office Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists."
07/27/2016	Revised to correct a typographical error(s).
07/07/2016	Modified to provide more succinct and clearer risk information for prescribers and pharmacists in the Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists Brochure, Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers Brochure the Appropriate Use Checklist, Dear Prescriber Letter, and Dear Pharmacist Letter.
08/10/2015	Modified to update language to permit the use of Zubsolv for the initial (“induction”) treatment of opioid dependence in the Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Pharmacists brochure and the Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers brochure.
06/04/2015	Modified to add a new strength of Zubsolv: 2.9 mg buprenorphine/ 0.71 mg naloxone to the REMS appended materials.
02/12/2015	Modified to: Add two new strengths of Zubsolv: 8.6 mg buprenorphine/ 2.1 mg naloxone and 11.4 mg buprenorphine/ 2.9 mg naloxone. Add Bunavail (buprenorphine/naloxone) buccal film product information. Change the indication for Suboxone (buprenorphine and naloxone) sublingual film to include the use of Suboxone (buprenorphine and naloxone) sublingual film in all phases of treatment for opioid dependence. Limitations of use in initial treatment to patients physically dependent on heroin or other short-acting opioids. Add a new warning regarding use in patients with hepatic impairment. Update language on use in pregnancy, nursing mothers, and patients with hepatic impairment.
06/06/2014	Modified to add Bunavail (buprenorphine and naloxone) product information to the shared system REMS.
09/04/2013	Modified to: Revise one of the goals to include informing prescribers and pharmacists of the serious risks associated with buprenorphine-containing products. Add a timetable for submission of assessments for the NDA holder(s) of the BTOD REMS. Update REMS materials to reflect the addition of a new product to the BTOD REMS including information on how the new product differs from the currently available products, how to switch between products, and recommended dosing.
02/22/2013	Approval of the REMS.

Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.